iiinova — where your digital self keeps evolving

RTI Health Solutions

@rti-hs.bsky.social

86 followers 102 following 42 posts

We partner with pharmaceutical and medical device developers to provide critical strategy and integrated evidence generation throughout product development lifecycles. www.rtihs.org

Posts Replies Media

RTI Health Solutions @rti-hs.bsky.social · 12/01/2026

“Putting patients first” gets talked about a lot—but what does it really mean in practice? For pharma and biotech, patient-centricity isn’t just the right thing to do. It’s becoming a business imperative for better evidence, smarter decisions, and stronger outcomes. ow.ly/veUz50XVz2Z

Putting patients first: from buzzword to business imperative

RTI Health Solutions @rti-hs.bsky.social · 08/12/2025

ISPOR Europe 2025 highlighted that patient voice drives #HTA, value, and access. PROs, COAs, preference evidence, real-world data, and #JCA all matter — integrate early for stronger, decision-ready submissions. Read more: ow.ly/9XnQ50XFTuS

ISPOR EU 2025 Recap Blog

RTI Health Solutions @rti-hs.bsky.social · 20/11/2025

ow.ly/y4I550XuUw1 EU Joint Clinical Assessments are reshaping orphan drug access in Europe. Download RTI Health Solutions’ free report for the key challenges, evidence needs, and strategies to stay ahead. #OrphanDrugs #RareDisease #JCA

Blueprint graphic with the number 1 and text: “Plan Early, Plan Smart.”

Blueprint graphic with the number 2 and text: “Build on Solid Strategy.”

Blueprint graphic with the number 3 and text: “Validate and Align Early.”

Blueprint graphic with the number 4 and text: “Be Ready—From Dossier to Decision,” plus a small image of the JCA report.

RTI Health Solutions @rti-hs.bsky.social · 07/11/2025

We're excited to announce that we've expanded our collaboration with Bekhealth and Innovo Research to set a new standard for how EHR data is transformed into actionable intelligence for clinical research and RWE. -> ow.ly/kqFm50Xo1mB #drugdevelopment #HealthOutcomes 🧪 PharmSky Medsky

RTI Health SOlutions expand partnership with Bekhealth and Innovo Research.

RTI Health Solutions @rti-hs.bsky.social · 25/09/2025

What happens when you need clear, expert-driven guidance on when and how a therapy should be used in clinical practice? We used a Delphi panel approach—bringing together expert consensus to inform treatment guidelines. See the case study -> ow.ly/e09o50WxrFb 🧪 PharmSky Medsky #medaffairs

RTI Health Solutions @rti-hs.bsky.social · 24/09/2025

What happens when you need clear, expert-driven guidance on when and how a therapy should be used in clinical practice? We used a Delphi panel approach—bringing together expert consensus to inform treatment guidelines for a client’s therapy. See the case study -> ow.ly/e09o50WxrFb 🧪 PharmSky Medsky

Delphi Panel on Proper Use of Anticoagulant Reversal Therapy in Life-Threatening Bleeds

Guiding the use of a treatment for life-threatening bleeds and creating convenient guides for emergency clinicians.

RTI Health Solutions @rti-hs.bsky.social · 18/09/2025

ow.ly/AksJ50WYfNS 🚀 Pharma innovation doesn’t end at approval—it begins with adoption. Why do some breakthrough therapies struggle to gain traction in the real world? Our latest whitepaper explores how Implementation Science can bridge the gap. 🧪 PharmSky Medsky

Drawing showing construction of a building with the title Leveraging Implementation Science for Sustainable Innovation.

RTI Health Solutions @rti-hs.bsky.social · 16/09/2025

Smarter pharma research starts with responsible AI. RTI Health Solutions is leading the way with: ✅ Validated Artificial Intelligence tools ✅ Human oversight ✅ Global compliance Let’s innovate with integrity.🔗Learn more about our approach at ow.ly/sN4550WXs2c #PharmaInnovation 🧪 PharmSky Medsky

hand pointing at shield with check mark on it. Text: Responsible AI in Health Science, RTI Health Solutions

RTI Health Solutions @rti-hs.bsky.social · 11/09/2025

Developing an ultra-rare disease therapy? Identifying a suitable comparator for pricing and reimbursement can be a big hurdle. Here's how we helped a client navigate complex global market access challenges with a strategic roadmap for regional value dossiers. ow.ly/NsNB50WxspH 🧪 PharmSky Medsky

RTI Health Solutions @rti-hs.bsky.social · 04/09/2025

What a week at #ISPEAnnual2025 in DC! From powerful sessions to meaningful connections, we left inspired. 💡 Check out the research we presented and follow-up with our team at ow.ly/V8Ee50WRx0R

RTI Health Solutions @rti-hs.bsky.social · 04/09/2025

Are you leveraging Implementation Science in your Pharma or MedTech research? This proactive, evidence-based model helps anticipate and overcome barriers to adoption—accelerating the integration of innovative therapies into clinical practice. Download the whitepaper at go.rti.org/LeverageImpSci

000

RTI Health Solutions @rti-hs.bsky.social · 03/09/2025

The TARGET Guideline for target trial emulation is now publicly available. This new guideline will improve reporting transparency of studies using real-world data to emulate a pragmatic randomized trial and improve clarity, completeness, and credibility of findings. Learn more at ow.ly/vLpa50WPPHr

RTI Health Solutions @rti-hs.bsky.social · 21/08/2025

🧬 A biopharmaceutical company needed to validate its health economic model for a rare disease across healthcare systems. See how RTI Health Solutions helped them navigate regional complexities and ensure their model stood up to scrutiny. ow.ly/t9ek50WxrwX Pharma Strategy, Value Assessment

Image of child in hospital bead with banner RTI hs Case Study and title of case study.

000

RTI Health Solutions @rti-hs.bsky.social · 14/08/2025

Join our webinar on the challenges and early learnings surrounding JCA guidelines for orphan drug development. Whether you're preparing for your first JCA submission or refining your approach, this session offers valuable insights. 📅 24 September 2025, 16:00 CEST/10:00 EDT 🔗 ow.ly/bQZ150WFVA0

Webinar: EU Joint Clinical Assessment for Orphan Drugs

Join our expert-led webinar on the EU Joint Clinical Assessment for orphan drugs to learn challenges and strategies for rare disease submissions

RTI Health Solutions @rti-hs.bsky.social · 06/08/2025

🌟 Empowering the Next Generation of Women in STEM! 🌟 We're proud to share that Mei Grace, Sr Research Health Economist at RTI-HS, spoke at Girls Talk Math at UNC Chapel Hill, inspiring students with her STEM journey. Her story sparked curiosity, engagement, and highlighted the power of mentorship.

MSc, MathematicsWake Forest University, Winston Salem, NC BS, MathematicsUniversity of Vermont, Burlington, VT

000

RTI Health Solutions @rti-hs.bsky.social · 16/07/2025

We’re proud to announce that we have earned a Bronze Medal Sustainability Rating from EcoVadis. This is a testament to our commitment to incorporate sustainable practices into our operations, ensuring we positively impact the environment and society. Learn more at ow.ly/zXj350WnUi1

RTI Health Solutions Recognized for Sustainable Management System

RTI Health Solutions has earned a Bronze Medal, a recognition awarded to the Top 35% of companies assessed by EcoVadis for the sustainability of the company's management system and commitment to promo...

RTI Health Solutions @rti-hs.bsky.social · 09/07/2025

There was an invigorating atmosphere of cooperation at the recent focusing on the 6-month assessment of new EU HTA, JCA regulation. Several of our researchers attended and share key insights. Read their observations here: ow.ly/HM1750WmB2Q 🧪 PharmSky Medsky HTA

A New Era of Collaboration for EU Health Technology Assessment

Learn about developments in the EU HTA regulation and the role of collaboration, AI, and capacity building in shaping the future of healthcare.

RTI Health Solutions @rti-hs.bsky.social · 10/06/2025

Next week on June 18, our experts will be hosting a webinar where they discuss methods and guidelines for establishing surrogate outcomes. Learn how they have been used in health technology assessments to date. Register today! ow.ly/BA9r50VOqLt 🧪 PharmSky Medsky HTA

Webinar: Surrogate Outcomes in Health Technology Assessment - Accelerating Access to Breakthrough Treatments

Surrogate outcomes play an important role in modern healthcare research. Join us for this webinar where our experts will focus on methods and guidelines for establishing surrogate outcomes and how the...

RTI Health Solutions @rti-hs.bsky.social · 03/06/2025

There's a lot of debate surrounding the use of artificial intelligence tools in research. At RTI Health Solutions, we prioritize responsible #AI use by adhering to these 5 key principles. ow.ly/riV150W3f6c Responsible AI, Human in the Loop, pharmaceutical development

Artificial Intelligence in Health Science: Advancing Research Responsibly and Ethically

While the use of artificial intelligence holds great promise, it also comes with risk. We help clients understand how to effectively use AI in their research.

RTI Health Solutions @rti-hs.bsky.social · 21/05/2025

RTI-HS experts share 5 critical steps during rare disease drug development that can help prepare your orphan drug to progress through joint clinical assessments (JCA). ow.ly/Q28e50VVWOJ 🧪 PharmSky Medsky

Joint Clinical Assessment and Orphan Drugs: 5 Steps to Success

JCAs will apply to orphan medicines starting in 2028. We’d like to share some of what we’ve learned from working on JCA submissions.

RTI Health Solutions @rti-hs.bsky.social · 21/05/2025

Hi Chris! Welcome to Bluesky. So glad you're here. 😃 - Samantha @csimmons913.bsky.social

000

RTI Health Solutions @rti-hs.bsky.social · 15/05/2025

Discover how the pharmaceutical industry can leverage implementation science to identify gaps and opportunities, enabling companies to craft research that aligns with long-term goals and delivers tangible value to all decision-makers. ow.ly/LAHU50VSPQS 🧪 PharmSky Medsky #ISPORAnnual

Why Implementation Science is Vital for Pharma Innovation

Learn how implementation science helps pharma improve adoption, outcomes, and value by embedding sustainable strategies into existing workflows.

RTI Health Solutions @rti-hs.bsky.social · 07/05/2025

You are invited to our June 18 webinar: Surrogate Outcomes in HTA. Explore real-world examples and challenges around using surrogate outcomes in HTAs, with examples in cardiovascular disease, oncology, and obesity. Learn more and register here ow.ly/BA9r50VOqLt 🧪 PharmSky Medsky

Webinar: Surrogate Outcomes in Health Technology Assessment - Accelerating Access to Breakthrough Treatments

Surrogate outcomes play an important role in modern healthcare research. Join us for this webinar where our experts will focus on methods and guidelines for establishing surrogate outcomes and how the...

000

RTI Health Solutions @rti-hs.bsky.social · 07/05/2025

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity. ow.ly/viaY50V2PES @John Seeger #observationalresearch #researchethics 🧪PharmSky #realworldevidence

Recognizing Futility in Research: When to Consider Discontinuing Observational Research

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity.

000

RTI Health Solutions @rti-hs.bsky.social · 29/04/2025

We are very proud that RTI has been recognized as one of America's Greenest Companies by Newsweek! We are serious about our commitment to corporate responsibility and #sustainability. Read more about this award. ow.ly/R1s550TWITy 🧪 PharmSky @rti.bsky.social

RTI recognized by Newsweek as one of America’s Greenest Companies

RTI was recognized as one of America’s Greenest Companies by Newsweek and Plant-A Insights Group in collaboration with GIST Impact.

RTI Health Solutions @rti-hs.bsky.social · 24/04/2025

The responsible use of AI tools in evidence synthesis is paramount. Thorough evaluation before deployment ensures that tools enhance efficiency without compromising quality. Jose Marcano Belisario, PhD of RTI Health Solutions shares his insights. ow.ly/myTL50VGjRf #ResponsibleAI 🧪 PharmSky Medsky

Harnessing AI Tools for Enhanced Evidence Synthesis: Lessons Learned

AI holds immense potential to address one of the most significant challenges in evidence synthesis: the sheer volume of work. See more.

RTI Health Solutions @rti-hs.bsky.social · 23/04/2025

Listen in on a discussion of research aimed at informing policy decisions around the prevention and care of RSV. The study reveals a considerable physical burden of RSV across the U.S. along with staggering costs. ow.ly/iP9v50UV78Y @AURN - American Urban Radio Networks 🧪 PharmSky Medsky

How Getting Sick Can Cost You Billions

Our experts discuss the complete economic burden of this disease and how you can stay healthy this winter.

000

RTI Health Solutions @rti-hs.bsky.social · 17/04/2025

It's a new era for patient access to health innovation. The EU Commission's Joint Clinical Assessment Rules on HTA are now in effect. Learn about what this era heralds: ow.ly/ImgU50UFFBI #JCA #jointclinicalassessment #patientaccess PharmSky HEOR

Joint Clinical Assessment Rules on Health Tech Assessment Now in Effect: New Era for Patient Access to Innovation

The EU’s health technology assessment framework, effective from January 2025, improves patient access to new cancer medicines and advanced therapies.

RTI Health Solutions @rti-hs.bsky.social · 16/04/2025

Are we asking the right questions to inform therapeutic research? John Seeger, PharmD, DrPH shares the steps to create a research question can serve as a compass, driving research in a productive and meaningful way. Read on- ow.ly/4jsj50VA3ZR 🧪 PharmSky Medsky Drug Research medical device research

Therapeutic Research – Are We Asking the Right Questions?

This article explores strategies and approaches to refining a research question, offering a guide to help researchers craft improved questions. See more.

RTI Health Solutions @rti-hs.bsky.social · 15/04/2025

We are thrilled that research on cost-effectiveness of HIV pre-exposure prophylaxis drugs coauthored by RTI-HS' Anita Brogan and Ashley Davis has been awarded Paper of the Year by CEVR. Learn more about the research - ow.ly/sSFF50VALTX 🧪 PharmSky Medsky Drug Research @tuftscevr.bsky.social

Award for Best Cost-Effectiveness Analysis Published in 2024

RTI-HS authors' research on HIV drugs has been named Paper of the Year by CEVR.

RTI Health Solutions @rti-hs.bsky.social · 10/04/2025

Welcome AJ Messina to RTI-HS as Head of Implementation Science! A recognized leader within pharma, AJ has been instrumental in bridging the gap between drug development and real-world adoption. We’re excited to have AJ on board! ow.ly/tN2250VocaC #pharmaceuticals 🧪 PharmSky

RTI Health Solutions Welcomes AJ Messina as Head of Implementation Science

AJ Messina has joined RTI-HS where he will play a key role in advancing Implementation Science within pharmaceutical research and development. Learn more.

RTI Health Solutions @rti-hs.bsky.social · 19/03/2025

The recording is here! If you missed our webinar on unlocking the full potential of literature reviews in your pharmaceutical or health technology asset development, you can watch it here-> ow.ly/i9Cn50V63Lm #pharmaceutical #healthtechnology #litreviews

000

RTI Health Solutions @rti-hs.bsky.social · 13/03/2025

In January 2028, a new era begins for orphan product manufacturers in Europe with Joint Clinical Assessments. Learn how changes will impact orphan drug approvals and how strategic planning can improve market success. ow.ly/T3GM50VhbOQ 🧪 PharmSky Medsky #JCA drug approval

Pave the Way to Joint Clinical Assessment for Your Orphan Drug in Europe

Learn how the 2028 Joint Clinical Assessment changes impact orphan drug approvals in Europe and how strategic planning can improve market success.

000

RTI Health Solutions @rti-hs.bsky.social · 11/03/2025

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity. ow.ly/viaY50V2PES written by John Seeger #observationalresearch #researchethics 🧪 PharmSky Medsky

Recognizing Futility in Research: When to Consider Discontinuing Observational Research

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity.

RTI Health Solutions @rti-hs.bsky.social · 10/03/2025

Ten Must‐Read Papers on Transparency and Reproducibility in Pharmacoepidemiology ow.ly/wgGL50VeMG How can we ensure quality and establish trust in research? Our contributions on the topic are featured in the PRINCIPLED and DIVERSE frameworks, and the HARPER protocol template 🧪 PharmSky Medsky

RTI Health Solutions @rti-hs.bsky.social · 04/03/2025

2 day course on Causal Inference from Observational Data. Includes practical use-case studies that apply to the target trial framework. Submit questions about your own target trial emulations. Learn more at ow.ly/3e4250UOSa0 #targettrial #epidemiology #biostatistics #causalinference 🧪

In-Person Course: Towards Regulatory-Grade Causal Inference from Observational Data

Bring your causal questions about real-world data to the experts

RTI Health Solutions @rti-hs.bsky.social · 27/02/2025

Learn to recognize the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity. ow.ly/viaY50V2PES #observationalresearch #researchethics 🧪PharmSky #realworldevidence

Recognizing Futility in Research: When to Consider Discontinuing Observational Research

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity.

000

RTI Health Solutions @rti-hs.bsky.social · 26/02/2025

Unlock the full potential of leveraging literature reviews in your pharmaceutical or health technology asset development strategy by joining our upcoming webinar. Learn more and register here. ow.ly/i9Cn50V63Lm #drugdevelopment #healthtech #litreviews

Webinar: Using Literature Reviews to Reveal the Benefits and Demonstrate the Value of Your Product

Unlock the full potential of leveraging literature reviews in your pharmaceutical or health technology asset development strategy by joining our upcoming webinar. Gain valuable insights into various a...

000

RTI Health Solutions @rti-hs.bsky.social · 19/02/2025

If you are working on health research studies with UK data, who is accessing, managing, and interpreting that data for you? Our researchers can determine whether CPRD data may be the best option for your research questions. ow.ly/fpc750UR4oT #realworldevidence #realworlddata 🧪PharmSky

RTI Health Solutions @rti-hs.bsky.social · 11/02/2025

It’s no longer enough to assess benefits and costs to healthcare payers; we must also capture broader societal effects on patients, families, and the economy. New HTA frameworks can better capture the value of medical innovations. #HealthTechnologyAssessment #HEOR 🧪 PharmSky #HealthEconomics

Rethinking Health Technology Assessment: Expanding Value Beyond Health Gains and Costs

Learn how new frameworks for HTAs can better capture the full value of medical innovations, including broader social impacts.

000

RTI Health Solutions @rti-hs.bsky.social · 11/02/2025

Decision Modelling for health economic evaluation has challenges when it comes to multicountry adaptations. Learn how streamlining model adaptations for #HTA submissions can bring efficiencies & compliance. ow.ly/L3N550USlJU #HealthTechnologyAssessment #HEOR 🧪 PharmSky #HealthEconomics #HEModelling

Optimizing Health Economic Modelling for Multicountry Adaptations

Learn how to streamline health economic models for multicountry adaptations, ensuring efficiency, compliance, and cost-effectiveness in HTA submissions.

RTI Health Solutions @rti-hs.bsky.social · 29/01/2025

@causalab.bsky.social and @rtihs.bsky.social invite you to this 2-day in-person course. Learn from case studies that apply to the target trial framework and ask questions about your own target trial emulations. Learn more and register at ow.ly/3e4250UOSa0 epidemiology biostatistics causal inference

In-Person Course: Towards Regulatory-Grade Causal Inference from Observational Data

Bring your causal questions about real-world data to the experts